Results 31 to 40 of about 98,309 (302)

Immunohistochemical analysis of PD-L1, CD4, CD8, CD20, and PU.1 expression in a dedifferentiated chondrosarcoma: the clinical and prognostic value

Alʹmanah Kliničeskoj Mediciny
Background: Dedifferentiated chondrosarcoma (DDCS) is a rare and extremely aggressive variant of mesenchymal bone tumors, with a biphasic structure represented by the classical chondrosarcoma elements, usually of low or intermediate grade, combined with ...
Olga V. Kovaleva, Irena V. Boulytcheva, Dmitrii V. Rogozhin, Alexei N. Gratchev, Polina L. Prishchep, Nikolay E. Kushlinskii   +5 more
doaj   +1 more source

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

, 2010
Rituximab, a monoclonal antibody which targets CD20 on B-cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success a substantial proportion of B-cell lymphomas are unresponsive or develop resistance ...
French, R.R., Johnson, P.W.M., Cox, Kerry L., Chan, Claude H.T., Johnston, David A., Glennie, Martin J., Jarrett, T.C., Glennie, M.J., Verbeek, Sjef, Chan, H.T.C., Dixon, S.V., Mora Vidal, Regina, Wijayaweera, Sahan S., Cragg, Mark S., Lim, Sean H., Dixon, Sandra V., Verbeek, J.S., French, Ruth R., Wijayaweera, S.S., Jarrett, Timothy C., Cragg, M.S., Kim, Hyung J., Kerr, Jonathan P., Vidal, R.M., Johnston, D.A., Lim, S.H., Cox, K.L., Kerr, J.P., Johnson, Peter W.M., Beers, Stephen A., Kim, H., Beers, S.A.   +31 more
core   +1 more source

ANTI-B CELL THERAPY OF AUTOIMMUNE DISEASES

Медицинская иммунология, 2014
. Our understanding of the multiple physiological and pathological functions of B-cells continues to expand at a fascinating rate. As pathogenic elements in the development of autoimmune diseases, B-cells have become the focus of new therapeutics.
A. L. Masliansky, V. I. Mazurov, E. G. Zotkin, E. P. Ilivanova, Areg A. Totolian   +4 more
doaj   +1 more source

Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma [PDF]

Journal of Pathology and Translational Medicine, 2016
Background: Immunohistochemical demonstration of CD20 in diffuse large B-cell lymphoma (DLBCL) is prerequisite not only for the diagnosis but also for assigning patients to rituximab-containing chemotherapy.
Chang Hwan Choi, Young Hoon Park, Joo Han Lim, Suk Jin Choi, Lucia Kim, In Suh Park, Jee Young Han, Joon Mee Kim, Young Chae Chu   +8 more
doaj   +1 more source

The different predictive effects of the intensity and proportion of CD20 expression on the prognosis of B‐lineage acute lymphocyte leukemia

eJHaem, 2022
The prognostic effects of the CD20 positivity have been studied extensively in B‐lineage acute lymphocyte leukemia (B‐ALL) patients, but the results remain controversial.
Yun Tian, Xiaojiao Wang, Hao Ai, Xiaodong Lyu, Qian Wang, Xudong Wei, Yongping Song, Qingsong Yin   +7 more
doaj   +1 more source

Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies [PDF]

mAbs, 2020
Current combination therapies elicit high response rates in B cell malignancies, often using CD20 antibodies as the backbone of therapy. However, many patients eventually relapse or develop progressive disease. Therefore, novel CD20 antibodies combining multiple effector mechanisms were generated.
Mitchell Evers, Toine Ten Broeke, J.H. Marco Jansen, Maaike Nederend, Firas Hamdan, Karli R. Reiding, Saskia Meyer, Petra Moerer, Iris Brinkman, Thies Rösner, Robert Jan Lebbink, Thomas Valerius, Jeanette H.W. Leusen   +12 more
openaire   +6 more sources

Helicobacter pylori and Gastric Mucosa-associated Lymphoid Tissue (MALT) Lymphoma: Updated Review of Clinical Outcomes and the Molecular Pathogenesis

Gut and Liver, 2009
In most H. pylori-positive patients, gastric low-grade mucosa-associated lymphoid tissue (MALT) lymphomas regress both endoscopically and histopathologically after H.
doaj   +1 more source

Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least
Kimberly H. Markowitz, Neha V. Safi, Iliana Pliska‐Bloch, Ulrike W. Kaunzner, Ha Luu, Mert Sisman, Yi Wang, Thanh D. Nguyen, Sandra Hurtado Rúa, Susan A. Gauthier   +9 more
wiley   +1 more source

Supplementary Figure S5 from Eradication of Canine Diffuse Large B-Cell Lymphoma in a Murine Xenograft Model with CD47 Blockade and Anti-CD20

, 2016
1E4 antibody binds canine CD20 extracellular domain 2.
Kipp Weiskopf (14997924), Amira Barkal (4723545), Kelly M. McKenna (10175765), Peter J. Schnorr (15114298), Jaime F. Modiano (8479011), Kristin Bloink (15114301), Timothy D. O'Brien (14929697), Ingrid Cornax (6420401), Hirotaka Tomiyasu (5148404), Daisuke Ito (95901), M. Gerard O'Sullivan (14911866), Jem Efe (15114304), Sarah Rue (15114307), Katie L. Anderson (9092708), Aaron M. Ring (9628714), Susan Prohaska (798035), David Lowery (157642), Irving L. Weissman (9758181)   +17 more
core   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source